Back to search
Acquired Nasolacrimal Duct Obstruction
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Acquired Nasolacrimal Duct Obstruction trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Acquired Nasolacrimal Duct Obstruction trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
Primary acquired nasolacrimal duct obstruction
Primary acquired nasolacrimal duct obstruction (PANDO) is a lacrimal duct obstruction disease characterized by inflammatory fibrosis of the nasolacrimal duct, w…
Primary acquired nasolacrimal duct obstruction causes persistent tearing because tears cannot drain normally from the eye into the nose. The purpose of this ran…
The aim of DCR is to form a new, mucosa-lined pathway between the lacrimal sac and the nasal cavity where tears can bypass a lacrimal obstruction and drain dire…